42602
Propionyl-L-carnitine
≥94.0% (HPLC), suitable for LC/MS
別名:
(2R)-3-Carboxy-N,N,N-trimethyl-2-(1-oxopropoxy)-1-propanaminium inner salt, L-Carnitine propionyl ester, C3-Carnitine, Propanoyl-L-carnitine
ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C10H19NO4
CAS番号:
分子量:
217.26
UNSPSC Code:
12352209
PubChem Substance ID:
NACRES:
NA.26
MDL number:
製品名
Propionyl-L-carnitine, ≥94.0% (HPLC)
SMILES string
[O-]C(C[C@@H](OC(CC)=O)C[N+](C)(C)C)=O
InChI
1S/C10H19NO4/c1-5-10(14)15-8(6-9(12)13)7-11(2,3)4/h8H,5-7H2,1-4H3/t8-/m1/s1
InChI key
UFAHZIUFPNSHSL-MRVPVSSYSA-N
assay
≥94.0% (HPLC)
form
powder or crystals
optical activity
[α]/D -23±3°, c = 1 in H2O
technique(s)
LC/MS: suitable
impurities
≤10% water (calcd. from elemental analysis)
color
white to off-white
storage temp.
2-8°C
Quality Level
類似した製品をお探しですか？ 訪問 製品比較ガイド
Application
Propionyl-L-carnitine has been used as a standard in liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Biochem/physiol Actions
Propionyl-L-carnitine (PLC) plays a key role in lipid and carbohydrate metabolism. It provides substrates to the ischemic muscle for energy production and ATP generation. PLC has the potential to treat severe peripheral arterial disease and chronic heart failure. It is present in high abundance in the urine of patients with methylmalonyl-CoA mutase (MUT) deficiency, together with methylmalonic acid. MUT is a mitochondrial enzyme that catalyzes the isomerization of methylmalonyl-CoA to succinyl-CoA.
General description
Propionyl-L-carnitine (PLC) is a short-chain fatty acid ester derivative of carnitine.
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
42602-VAR: + 42602-BULK: + 42602-10MG: + 42602-50MG:
jan
William R Hiatt et al.
Journal of cardiopulmonary rehabilitation and prevention, 31(2), 125-132 (2010-09-24)
Exercise training is established for the treatment of peripheral artery disease; however the additional benefit of pharmacologic therapy with exercise has not been studied. This trial tested the hypothesis that propionyl-L-carnitine (PLC), in combination with monitored home-based exercise training, would
Carmen Mingorance et al.
Nutrition reviews, 69(5), 279-290 (2011-04-28)
Propionyl-L-carnitine (PLC) is a naturally occurring derivative of carnitine that plays an important role in the metabolism of both carbohydrates and lipids, leading to an increase of ATP generation. PLC, however, is not only a metabolic drug; it is also
M J Cipolla et al.
Journal of vascular surgery, 29(6), 1097-1103 (1999-06-09)
The vasoactive effects of propionyl-L-carnitine (PLC) on human arteries, including endothelial and smooth muscle cell influences, were studied. Small (less than 200 microm) subcutaneous fat arteries (n = 19), obtained from human patients undergoing vascular surgery, were dissected and mounted
Santica M Marcovina et al.
Translational research : the journal of laboratory and clinical medicine, 161(2), 73-84 (2012-11-10)
Mitochondria play important roles in human physiological processes, and therefore, their dysfunction can lead to a constellation of metabolic and nonmetabolic abnormalities such as a defect in mitochondrial gene expression, imbalance in fuel and energy homeostasis, impairment in oxidative phosphorylation
Qixiao Jiang et al.
Environmental toxicology and pharmacology, 48, 116-124 (2016-10-25)
Perfluorooctanoic acid (PFOA), a persistent organic pollutant, is associated with developmental toxicity. This study investigated the mechanism of PFOA-induced developmental cardiotoxicity in chicken embryo, focusing on the interactions between developmental exposure to PFOA and the levels of l-carnitine (LC), acetyl-l-carnitine
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）